Education
About Us
Working with TipRanks
Follow Us
Lipigon Pharmaceuticals AB (SE:LPGO)
:LPGO
Top Page
Lipigon Pharmaceuticals AB
(LPGO)
Select Model
Select Model
Rating:40Underperform
Price Target:
kr0.01
▲(30.00% Upside)
The score is held down primarily by sustained losses and significant ongoing cash burn (negative OCF/FCF), which increases financing risk, alongside very bearish technicals with the stock far below major moving averages and negative MACD. A debt-free balance sheet is a modest stabilizer, but negative earnings also limit valuation support and no dividend data is provided.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet materially lowers solvency risk, reducing fixed interest costs and giving management flexibility to pursue R&D or partnership deals without near-term debt servicing constraints. This structural strength eases financing pressure during product development cycles.
Focused RNA-based therapeutic niche
A clear focus on RNA therapies for cardiometabolic disorders creates a durable competitive positioning: deep domain expertise, targeted R&D pipelines, and alignment with long-term scientific and commercial trends toward nucleic-acid medicines, making the company an attractive partner for larger players.
Partnering/licensing monetization pathway
R&D-stage biotech models that rely on licensing and partnerships allow value realization without building commercial infrastructure. Durable upside comes from upfront and milestone payments and access to partners' late-stage development and commercialization capabilities, reducing go-to-market burden.
Negative Factors
Persistent negative cash flow / high cash burn
Sustained, large negative operating and free cash flows increase structural funding risk: management must raise capital or cut R&D, diluting shareholders or delaying programs. Over months, persistent burn can curtail development timelines and weaken negotiating leverage with partners.
Very low and volatile revenues
Minimal and declining revenue constrains internal funding capacity and signals limited near-term commercialization progress. Low top-line coupled with negative margins limits operating leverage and forces continued reliance on external financing, elevating execution risk over the medium term.
Clinical-stage with no marketed products
Being clinical-stage without marketed products makes long-term cash flow contingent on trial outcomes, regulatory approval, or partner deals. This structural dependency on successful development and external financing increases uncertainty and the potential for program disruption or dilution.
Lipigon Pharmaceuticals AB (LPGO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr4.97M
Dividend YieldN/A
Average Volume (3M)2.79M
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding605,933,700
10 Day Avg. Volume2,063,232
30 Day Avg. Volume2,789,495
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.06
Price to Sales (P/S)1.55
P/FCF Ratio-0.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lipigon Pharmaceuticals AB Business Overview & Revenue Model
Company DescriptionLipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.
How the Company Makes Money
Lipigon Pharmaceuticals AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.36M | 10.29M | 16.41M | 390.00K | 3.18M | 4.28M |
| Gross Profit | -23.95M | -26.29M | -5.12M | 366.00K | -36.04M | -4.72M |
| EBITDA | -35.56M | -25.14M | -12.10M | -37.68M | -41.09M | -8.06M |
| Net Income | -35.97M | -25.26M | -12.13M | -37.67M | -41.12M | -8.07M |
Balance Sheet | ||||||
| Total Assets | 18.08M | 14.82M | 33.60M | 10.82M | 29.43M | 15.24M |
| Cash, Cash Equivalents and Short-Term Investments | 16.60M | 11.78M | 31.93M | 9.64M | 28.47M | 12.55M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 2.99M | 7.06M | 5.16M | 6.95M | 6.47M | 2.26M |
| Stockholders Equity | 15.09M | 7.76M | 28.45M | 3.87M | 22.96M | 12.98M |
Cash Flow | ||||||
| Free Cash Flow | -28.43M | -25.02M | -14.32M | -37.47M | -35.42M | -8.63M |
| Operating Cash Flow | -28.33M | -24.78M | -14.32M | -37.47M | -35.30M | -8.63M |
| Investing Cash Flow | -108.00K | -235.00K | 0.00 | 0.00 | -119.00K | 1.25M |
| Financing Cash Flow | 34.32M | 4.58M | 36.70M | 18.61M | 51.09M | 18.88M |
Lipigon Pharmaceuticals AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.07
-82.72%
DE:5KC
PILA PHARMA AB
0.17
-0.18
-51.60%
DE:7UX
Spago Nanomedical AB
0.01
0.00
0.00%
DE:COJ0
CombiGene AB
0.16
<0.01
1.94%
DE:5JA1
Sprint Bioscience AB
0.16
0.04
35.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.